_MACHINE TRANSLATION_
The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”), hereby announces that today it became aware that on 9 January 2026 the Management Board of the Warsaw Stock Exchange S.A. (the “WSE”) adopted Resolution No. 18/2026 on the admission and introduction to exchange trading on the WSE Main Market of the Company’s ordinary bearer shares of series O (the “Resolution”).
Pursuant to the Resolution, the Management Board of the WSE resolved to: (i) state the admission to exchange trading on the parallel market operated by the WSE of 150,000 (one hundred and fifty thousand) ordinary bearer shares of series O of the Company (the “Shares”), and (ii) introduce the Shares to exchange trading on that market as of 14 January 2026, subject to the registration of the Shares by the National Depository for Securities S.A. (Krajowy Depozyt Papierów Wartościowych S.A.) on that date and the designation of the Shares with ISIN code PLBCLTX00019.
Signatures of persons representing the Company:
Łukasz Bzdzion – President of the Management Board
Paweł Wielgus – Member of the Management Board
_MACHINE TRANSLATION_